Danazol in menorrhagia: a double blind placebo controlled trial

Martin Lamb
In: Journal of Obstetrics and Gynaecology · 1987 · vol. 7(3) , pp. 212–216 · doi:10.3109/01443618709068521 · W2165891135
RCT OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Danazol 200 mg daily significantly improved symptomatic primary menorrhagia in a double-blind, placebo-controlled trial, with a carry-over effect lasting up to 4 months post-treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

SummaryIn a double blind study danazol was compared with placebo in the treatment of symptomatic primary menorrhagia. Seventy-six patients were assigned at random either danazol 200 mg daily or a matching placebo for 3 months. with subsequent observation for up to 6 months. Menstmation was assessed subjectively. Significant improvement, which was maintained for up to 4 months after treatment, was seen only with danazol. No serious side effects were encountered, although relatively minor symptomatic complaints interrupted danazol treatment in five patients and placebo in one. This study confirms that danazol 200 mg daily is effective in controlling symptomatic primary menorrhagia. A 3 month course has a 'carry over' effect which appears to be clinically useful.Danazol. a 2, 3 isoxazole derivative of 17-ethinyl testosterone, is an accepted treatment for endomet-riosis (Greenblatt et al., 1971; Luciano, 1982) and is known to suppress menstrual bleeding. Its value in the treatment of primary menorrhagia defined by blood loss exceeding 80 ml per month has been reported. In previous studies it was found that a 3 month course of danazol, 200 mg daily, substantially reduced menstrual blood loss and provided a 'carry over' effect for 2 to 3 months (Chimbira et al., 1979. 1980).In the present study we sought to confirm and extend previous findings, and compared danazol with placebo under double blind conditions in patients with primary menorrhagia defined by symptoms. The follow up period was extended to 6 months in order to ascertain the duration of any post-treatment benefit.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK